Becton, Dickinson and Company (NYSE:BDX) Reaches New 1-Year High - What's Next?

Key Points

• BDX reached a new 52-week high, trading as high as $187.92 and most recently around $186.75, up from its prior close of $180.77.
• Analyst sentiment is mixed but leans cautiously positive: 8 analysts rate the stock Buy, 8 Hold and 1 Sell. The consensus rating is Hold, with an average price target of $185.67.
• The company beat quarterly expectations with adjusted earnings of $3.23 per share and revenue of $4.98 billion, while declaring a quarterly dividend of $1.05 per share, equivalent to a 2.3% yield.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report)'s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $187.92 and last traded at $186.7470, with a volume of 409092 shares trading hands. The stock had previously closed at $180.77.

Analyst Ratings Changes

A number of research firms have commented on BDX. Barclays upped their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research report on Monday, May 11th. Jefferies Financial Group restated a "buy" rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. UBS Group initiated coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price target for the company. Weiss Ratings reissued a "sell (d+)" rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Royal Bank Of Canada upped their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $185.67.

Becton, Dickinson and Company Price Performance

The stock has a market cap of $51.31 billion, a P/E ratio of 56.09, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The firm has a 50-day moving average price of $159.06 and a 200-day moving average price of $161.12.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company's stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 11,779 shares of company stock worth $1,974,669. 0.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of institutional investors have recently made changes to their positions in BDX. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company during the third quarter valued at $25,000. SHP Wealth Management bought a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $29,000. WPG Advisers LLC boosted its holdings in Becton, Dickinson and Company by 64.2% in the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 61 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source